CurvaFix, Inc., a Bellevue, Wash.-based developer of medical devices to repair fractures in curved bones, closed a $10.75m Series B equity financing.
The round was led by Sectoral Asset Management with participation from existing investors Delta Dental Washington Seed Fund, and board members. In conjunction with the funding, Sectoral Asset Management’s Michael Sjöström and Marc-André Marcotte joined CurvaFix’ board of directors.
The company plans to use the funds to complete the RESTORE Clinical Study and begin commercialization activities.
Led by Steve Dimmer, chief executive officer, CurvaFix is a medical device company advancing an implant focused on improving outcomes and simplifying surgery for orthopedic trauma patients suffering from pelvic fractures. The patented CurvaFix® Intramedullary Rodscrew is capable of following the natural bone curvature of the pelvis. The device has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for fixation of pelvic fractures and is currently the focus of the CurvaFix sponsored RESTORE Study. The RESTORE Study is gathering clinical evidence to support the CurvaFix System’s potential benefits for pelvic fracture patients in advance of a U.S. commercial launch.